Hoechst Aktiengesellschaft

Behringwerke Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Hoechstaktiengesellschaft

Rolf Muller

Hans-Harald Sedlacek

Klaus Bosslet

Peter Hermentin

Hans H Sedlacek

Bernhard Auerbach

Peter Pfleiderer

Thomas Kissel

Hans-Dieter Klenk

Marisa Wick

The present invention relates to a cell cycle regulated repressor protein which binds to a DNA element present in the control sequences of the human cdc25C gene and other cell cycle regulated genes, as well as the use thereof in cell cycle regulated expression systems.

Cell cycle regulated repressor and DNA element

Target cell-specific, non-viral vectors for inserting genes into cells, pharmaceuticals composition comprising such vectors, and methods of their use. Target cell-specific, non-viral vectors for inserting at least one gene into cells of an organism, comprising a complex comprising the following components:

Target cell-specific non-viral vectors for inserting genes into cells,

The invention relates to promoter sequences for a gene comprising a tissue inhibitor of metalloproteinase-3 (TIMP-3). This inhibitor is found in particular in macrophages, synovial cells, and connective tissue cells. The invention also relates to cell-specific gene therapy of a subject, wherein expression of a gene in a tissue is regulated by the aforementioned promoter sequence operationally coupled to said gene. The promoter may also be used in diagnostic methods.

Cell-specific gene therapy using as promoter novel promoters for tissue

Gene therapy of tumors with an endothelial cell-specific, cell

The invention relates to a method of using a pair of leucine zipper peptides for in vitro diagnosis, in particular, for the immunochemical detection and determination of an analyte in a biological liquid. In one method, the first leucine zipper peptide is immobilized by attaching it to a solid support, the second leucine zipper peptide is coupled to a specific binding partner for the analyte, the two peptides are brought into contact, the sample of the biological liquid is brought into contact with the immobilized first peptide and the specific binding partner for the analyte, and the amount of analyte bound to the binding partner is determined. The leucine zipper peptides are preferably v-fos and c-jun.

Use of pairs of leucine zipper peptides in immunoassay methods

Growing community of inventors

Marburg, Germany

Rolf Muller